Of the 5 individuals infected with HCV genotype one or two 2 who were classified as not having a sustained virologic response at week 12 after treatment, 3 had missing data at week 12 but acquired a sustained virologic response at week 24 after treatment and 2 had been lost to follow-up. Among the 18 sufferers with HCV genotype 3 contamination, virologic relapse happened in 1 of 5 patients with a preexisting daclatasvir-resistant variant, and in another patient, who did not have preexisting daclatasvir-resistant variants, an HCV RNA level below 25 IU per milliliter was detected at weeks 8 and 10. Although HCV RNA was undetectable at week 12, this response design was predefined in the initial protocol as virologic breakthrough, and rescue therapy was initiated. Due to low virus levels through the treatment period and a sustained virologic response at week 12 after treatment, we’re able to not assess the part of viral variants in this individual.Torrey Pines Institute for Molecular Research, San Diego, CA, Clemencia Pinilla, Ph.D. Concentrate: T-cell epitopes of smallpox infections. Oregon Health and Science University, Portland, David Lewinsohn, M.D., Ph.D. Focus: T-cell epitopes of the bacteria that cause multi-medication resistant tuberculosis. University of Copenhagen, Denmark, Soren Buus, Ph.D. Concentrate: developing mathematical tools that more accurately predict the location of T-cell epitopes in genomes of potential brokers of bioterrorism. Centre for Biological Sequence Analysis at the Complex University of Denmark, Ole Lund, Ph.D. Concentrate: developing mathematical equipment that more accurately predict the positioning of T-cell epitopes in genomes of potential agents of bioterrorism.